EverSource Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

EverSource Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.04K	Buy	2,946 +141	+5%	+$545	﹤0.01%	2964
2025 Q4	$11.5K	Sell	2,805 -6,100	-69%	-$30.2K	﹤0.01%	2727
2025 Q3	$43.5K	Buy	8,905 +1,625	+22%	+$8.53K	﹤0.01%	1799
2025 Q2	$36.8K	Sell	7,280 -101,349	-93%	-$498K	﹤0.01%	1825
2025 Q1	$575K	Buy	108,629 +108,514	+94,360%	+$791K	0.03%	352
2024 Q4	$777	Buy	+115	New	+$773	﹤0.01%	3052
2024 Q3	–	Sell	-64	Closed	-$525	–	3109
2024 Q2	$525	Buy	+64	New	+$558	﹤0.01%	2879

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EverSource Wealth Advisors's RXRX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 5% in Q1 2026, buying an estimated $545 and bringing the position to 2,946 shares worth $9.04K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

EverSource Wealth Advisors first reported a position in RXRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $575K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

EverSource Wealth Advisors held 2,946 shares of Recursion Pharmaceuticals worth $9.04K as of Q1 2026.
EverSource Wealth Advisors bought 141 Recursion Pharmaceuticals shares in Q1 2026, an estimated $545.
Recursion Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #2964 holding.
EverSource Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
EverSource Wealth Advisors's Recursion Pharmaceuticals position peaked at $575K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.